Fig. 3: IL-13 does not modulate efficacy of anti-opioid vaccines.
From: Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders
Balb/c mice were immunized on days 0, 14, and 28 with either sKLH or OXY-sKLH. Concurrently, αIL-4 mAb, αIL-13 mAb, or both were administered on days −2 and 1 at a dose of 0.5 mg per mAb per dose. Mice were challenged s.c. with 2.25 mg/kg oxycodone. Oxycodone-specific antibody titers expressed as: (a) IgG at 14 days, (b) IgG at 34 days, and (c) ratio of IgG2a to IgG1. At 30 min post-drug challenge, concentration of oxycodone in (d) serum and (e) brain. Data are mean ± SEM. Sample size: n = 5–6 per group. Statistical analysis conducted by one-way ANOVA with Tukey’s multiple comparisons post hoc test. Symbols: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 compared to control, or brackets to indicate differences between groups.
